A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment
Web of Science
AuthorMandel, J; Bertrand, V; Lehert, P; Attarian, S; Magy, L; Micallef, J; Chumakov, I; Scart-Gres, C; Guedj, M; Cohen, D
Source TitleOrphanet Journal of Rare Diseases
PublisherBIOMED CENTRAL LTD
University of Melbourne Author/sLehert, Philippe
AffiliationMedicine and Radiology
Document TypeJournal Article
CitationsMandel, J., Bertrand, V., Lehert, P., Attarian, S., Magy, L., Micallef, J., Chumakov, I., Scart-Gres, C., Guedj, M. & Cohen, D. (2015). A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. ORPHANET JOURNAL OF RARE DISEASES, 10 (1), https://doi.org/10.1186/s13023-015-0293-y.
Access StatusOpen Access
CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a weak deterioration in patients under Placebo, well below the reported natural disease progression. Patients treated with AA were stable after one year but not significantly different from Placebo. Patients undergoing PXT3003 treatment showed an improvement in CMTNS and ONLS, statistically significant versus Placebo and potentially precursory of a meaningful change in the disease course.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References